Nuclear Imaging

Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. 

The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer
Feature | Radiation Oncology | By Vinay Shivaprasad
The Rise of Therapeutic Radiopharmaceuticals

The term nuclear medicine is associated with the diagnostic procedures single-photon emission computed tomography (SPECT ...

Time May 04, 2021
arrow
Sponsored Content | Blog | Contrast Media Injectors
BLOG: Smart Injector Technology Delivers Effective and Efficient Patient Care

Technology advancements are changing consumers’ expectations, driving industries to adapt and evolve, and the healthcare ...

Time April 29, 2021
arrow
olecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).
News | PET Imaging
Molecular Targeting Technologies, Inc. Announces New PET Imaging Agent

April 19, 2021 — Molecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953 ...

Time April 19, 2021
arrow
The inflamed joints of a #rheumatoid #arthritis patient are clearly visible in the #PET images with the novel 68Ga-DOTA-Siglec-9 #radiopharmaceutical. Image courtesy of Anne Roivainen
News | PET Imaging
Promising Results from First-in-humans Study of a Novel PET Radiopharmaceutical

April 19, 2021 — The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed ...

Time April 19, 2021
arrow
#NorthStar Medical #Radioisotopes, LLC, a global innovator in the development, production and commercialization of #radiopharmaceuticals used for #medicalimaging and #therapeutic applications, announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress

April 16, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 16, 2021
arrow
Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute
News | Breast Imaging
Configuring Infrared Spectroscopy Tools to Better Detect Breast Cancer

April 14, 2021 — Detecting and analyzing breast cancer goes beyond the initial discovery of the cancer itself. If a ...

Time April 14, 2021
arrow
ScImage, Inc. celebrates its cloud partnership with Digirad Health (“Digirad”), a division of Star Equity Holdings, after a year of successful deployment of PICOM365 for mobile imaging. Digirad’s fleet of mobile SPECT, echocardiology, vascular and general ultrasound units combined with PICOM365’s cloud image management workflow leverage each company’s strengths to create an exemplary reading and reporting environment.
News | Archive Cloud Storage
ScImage Celebrates Cloud Partnership with Digirad Health

March 30, 2021 — ScImage, Inc. celebrates its cloud partnership with Digirad Health (“Digirad”), a division of Star ...

Time March 30, 2021
arrow
News | PET-CT
PET/CT Shows Stressed Brain Linked to Broken Heart

March 29, 2021 — Heightened activity in the brain, caused by stressful events, is linked to the risk of developing a ...

Time March 29, 2021
arrow
Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status
News | Radiopharmaceuticals and Tracers
Shine Medical Announces its Isotope Production Facility is Weathertight

March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of-a ...

Time March 26, 2021
arrow
NorthStar poised to be first commercial-scale supplier of important therapeutic radioisotopes Copper-67 (Cu-67) and Actinium-225 (Ac-225); Initial specialized SPECT imaging portfolio includes fibrin-targeted FibroScint, with potential indications in cardiovascular disease
News | SPECT Imaging
NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals

March 16, 2021 — NorthStar Medical Radioisotopes, LLC announced organizational changes to drive focused growth for its ...

Time March 16, 2021
arrow
The phantom used for hyperpolarized imaging, with an illustration of imaging slices acquired using the new technique. photo/©: Laurynas Dagys, University of Southampton
News | Nuclear Imaging
Hyperpolarized Proton MRI Used to Observe Metabolic Processes in Real Time

March 12, 2021 — Magnetic resonance imaging (MRI) is already widely used in medicine for diagnostic purposes ...

Time March 12, 2021
arrow
Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world
News | Nuclear Imaging
IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m

March 8, 2021 — IBA (Ion Beam Applications S.A., EURONEXT) and NorthStar Medical Radioisotopes, LLC, announced a ...

Time March 08, 2021
arrow
Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Biograph Vision Quadra, a positron emission tomography/computed tomography (PET/CT) scanner designed for clinical use as well as translational research – or the application of scientific research to create therapies and procedures that improve health outcomes. In this manner, the Biograph Vision Quadra expands precision medicine.
News | PET-CT
Siemens Healthineers Announces FDA Clearance of Biograph Vision Quadra Extended Axial FoV PET/CT Scanner

March 8, 2021 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Biograph ...

Time March 08, 2021
arrow
Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.
Feature | Treatment Planning | By Melinda Taschetta-Millane
Using PET to Enhance Prostate Treatment Planning

The decision to offer radiation after prostatectomy for patients with recurrent prostate cancer is quite complex, and ...

Time March 05, 2021
arrow
CT imaging radiation dose tracking software from Imalogix displayed at RSNA 2019.
Feature | Radiation Dose Management | By Dave Fornell
Medical Imaging Radiation Exposure in U.S. Dropped Over Past Decade

More than a decade ago, there was an alarming, rapid rise in ionizing radiation exposure in the U.S. population that was ...

Time March 04, 2021
arrow
Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer
News | PET-CT
Model Helps Predict Which Patients will Benefit Most from PSMA PET Scan

February 23, 2021 — A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which ...

Time February 23, 2021
arrow
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.
News | Molecular Imaging
Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment

February 22, 2021 — Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2 ...

Time February 22, 2021
arrow
Bright spots indicate that cancer cells have responded to a one-day challenge with estrogen in this positron emission tomography (PET) scan of a woman with breast cancer. In a small study, researchers at Washington University School of Medicine in St. Louis found that only women whose tumors responded to estrogen challenge benefited from hormone therapy. The findings could help doctors choose the treatments most likely to help their patients. Image courtesy of Farrokh Dehdashti
News | PET Imaging
Imaging Identifies Breast Cancer Patients Unlikely to Benefit from Hormone Therapy

February 3, 2021 — Hormone therapy commonly is given as a targeted treatment for women whose cancer cells carry ...

Time February 03, 2021
arrow
NMP to evaluate technology to create new class of PET radiopharmaceuticals
News | PET Imaging
Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement

January 29, 2021 — Fuzionaire Radioisotope Technologies K.K. (“FRIT”) announced that it has entered into a feasibility ...

Time January 29, 2021
arrow
Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging
News | PET Imaging
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

January 18, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time January 18, 2021
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now